RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia

British Journal of Haematology

Volumn 146, Issue 6, 2009, Pages 665-668

  Schnittger, Susanne ^a   Bacher, Ulrike ^b   Kern, Wolfgang ^a   Tschulik, Claudia ^a   Weiss, Tamara ^a   Haferlach, Claudia ^a   Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bcr abl1; Chronic myeloid leukaemia; Clonal evolution; Imatinib; WT1

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; WT1 PROTEIN;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; RETROSPECTIVE STUDIES; WT1 PROTEINS; YOUNG ADULT;

EID: 71949092184     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07812.x     Document Type: Article

References (14)

1. Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., Apperley, J., Cervantes, F., Cortes, J., Deininger, M., Gratwohl, A., Guilhot, F., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Niederwieser, D., Silver, R. & Hehlmann, R. (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108, 1809-1820.
2. Cilloni, D. & Saglio, G. (2003) Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. Seminars in Hematology, 40, 37-41.
3. Cilloni, D. & Saglio, G. (2004) WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematologica, 112, 79-84.
4. Emig, M., Saussele, S., Wittor, H., Weisser, A., Reiter, A., Willer, A., Berger, U., Hehlmann, R., Cross, N.C. & Hochhaus, A. (1999) Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia, 13, 1825-1832.
5. Inoue, K., Ogawa, H., Sonoda, Y., Kimura, T., Sakabe, H., Oka, Y., Miyake, S., Tamaki, H., Oji, Y., Yamagami, T., Tatekawa, T., Soma, T., Kishimoto, T. & Sugiyama, H. (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood, 89, 1405- 1412.
6. Jabbour, E., Kantarjian, H.M., Abruzzo, L.V., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Shan, J., Rios, M.B. & Cortes, J. (2007) Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood, 110, 2991-2995.
7. Miwa, H., Beran, M. & Saunders, G.F. (1992) Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia, 6, 405-409.
8. Miyagi, T., Ahuja, H., Kubota, T., Kubonishi, I., Koeffler, H.P. & Miyoshi, I. (1993) Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia, 7, 970-977.
9. Na, I.K., Kreuzer, K.A., Lupberger, J., Dorken, B. & le Coutre, P. (2005) Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/ abl + CML. Leukemia Research, 29, 343-345.
10. Schoch, C., Schnittger, S., Bursch, S., Gerstner, D., Hochhaus, A., Berger, U., Hehlmann, R., Hiddemann, W. & Haferlach, T. (2002) Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia, 16, 53-59.
11. Tamaki, H. & Ogawa, H. (2004) Monitoring of minimal residual disease using WT1 assay for patients with chronic myeloid leukemia who undergo allogeneic stem cell transplantation. Bone Marrow Transplantation, 34, 653-654.
12. Uzunel, M. & Ringden, O. (2004) Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplantation, 33, 47-52.
13. Weisser, M., Kern, W., Rauhut, S., Schoch, C., Hiddemann, W., Haferlach, T. & Schnittger, S. (2005) Prognostic impact of RT-PCRbased quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia, 19, 1416-1423.
14. Wiktor, A., Rybicki, B.A., Piao, Z.S., Shurafa, M., Barthel, B., Maeda, K. & Van Dyke, D.L. (2000) Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer, 27, 11-16.